Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03936049 · ClinicalTrials.gov registry record
Replication of the LEADER Diabetes Trial in Healthcare Claims
A clinical trial of Diabetes, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 168,690
- Enrollment target
- 1
- Study location
NCT03936049: Completed study of Diabetes, sponsored by Brigham and Women's Hospital.
NCT03936049 is a study of Diabetes that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 168,690 participants, above the 2,529-participant average among 338 other Diabetes trials with a reported enrollment target (6570% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03936049, a study of Diabetes, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 168,690 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Relative hazard of composite outcome of MI, stroke, and mortality - Please refer to uploaded protocol for full definition due to size limitations.
Conditions Studied
Interventions
- DRUG Liraglutide
- DRUG DPP-4 inhibitor
Study Locations (1)
Massachusetts
- Brigham And Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168,690 participants |
| Start Date | 2017-09-22 |
| Est. Completion | 2021-02-18 |
What the finished NCT03936049 record still lists
NCT03936049 is an observational study that tracks outcomes without assigning an intervention. Its 168,690 participants enrollment target places it among the larger protocols in the corpus, above the 2,529-participant average among 338 other Diabetes trials with a reported enrollment target (6570% higher).
The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Liraglutide is the first listed.
NCT03936049 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03936049 about?
NCT03936049 is a clinical study titled "Replication of the LEADER Diabetes Trial in Healthcare Claims". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT03936049?
This trial is currently completed. The enrollment target is 168,690 participants. The study started on 2017-09-22. Estimated completion is 2021-02-18.
What conditions does trial NCT03936049 study?
This clinical trial studies the following conditions: Diabetes.
What interventions are being tested in trial NCT03936049?
The interventions under investigation include: Liraglutide (DRUG), DPP-4 inhibitor (DRUG).
Who is sponsoring clinical trial NCT03936049?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03936049 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03936049's enrollment target sits among peer trials
168,690 2nd of 338 the highest of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DFC 004 Biomarkers for Active Diabetic Foot Ulcers
RECRUITING
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Taste Bud-Derived Stem Cells in Humans
RECRUITING
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI